Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 juil. 2024 06h00 HE | Source: Immuron Limited

Immuron requests pre-IND meeting for IMM-529 with FDA filing

MELBOURNE, Australia, July 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that...
22 juin 2023 06h00 HE | Source: Immuron Limited

Immuron Business Update: Letter to Shareholders

Highlights: Immuron Board approves IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submissionRecruitment and screening update for Travelan® Controlled Human Infection Model (CHIM)...
17 janv. 2023 07h10 HE | Source: Immuron Limited

Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease

MELBOURNE, Australia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...
07 juil. 2022 06h00 HE | Source: Immuron Limited

Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease

MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...